<DOC>
	<DOCNO>NCT00908414</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , plasma pharmacokinetics ( i.e. , level TMC589337 TMC589354 circulate blood time ) increase single oral dos TMC589337 TMC589354 multiple increase oral dos follow single dose TMC310911 assess potential boost effect latter compound . In study 3 investigational new drug involve . These new investigational drug call TMC589337 TMC589354 ( PEPI family ) TMC310911 process development treatment Human Immunodeficiency Virus-Type 1 ( HIV-1 ) . TMC589337 TMC589354 novel molecule antiviral activity use enhance pharmacokinetics profile drug . TMC310911 novel potent compound belong medication class call protease inhibitor ( PI ) .</brief_summary>
	<brief_title>PEPI-TiDP23-C104 First Human Study With Single Dose Escalation Part Multiple Dosing Part Compounds TMC589337 TMC589354 .</brief_title>
	<detailed_description>This First-in-Human Phase I , double-blind ( neither physician patient know name assign study drug ) , randomize ( study medication assign chance ) , placebo-controlled ( group study participant receive inactive substance place medication ) trial examine safety , tolerability , plasma pharmacokinetics ( pk ) increase single oral dos TMC589337 TMC589354 , open-label ( physician study participant know name assign study drug ) part different repeat oral dos combination single oral dose TMC310911 assess potential pharmacokinetic enhancement latter compound . TMC589337 TMC589354 molecule use enhance pharmacokinetics profile drug , e.g. , Human Immunodeficiency Virus-Type 1 ( HIV-1 ) protease inhibitor ( PI ) . TMC310911 investigational PI , currently study healthy volunteer . The trial consist 2 part : single dose escalation part ( double-blind , placebo-controlled ) multiple dose part ( open label ) PEPI-compounds : TMC589337 TMC589354 . The single dose escalation part trial include 2 panel 8 healthy adult volunteer ( Panel 1 2 ) . Each panel 4 oral escalate single dose session either TMC589337 ( Panel 1 ) TMC589354 ( Panel 2 ) . Healthy volunteer receive dos 40 mg ( Session Ia ) , 100 mg ( Session IIa ) , 200 mg ( Session IIIa ) 400 mg ( Session IVa ) TMC589337 placebo . Panel 2 receive dos 40 mg ( Session Ib ) , 100 mg ( Session IIb ) , 200 mg ( Session IIIb ) 400 mg ( Session IVb ) TMC589354 placebo . Both panel run parallel . In session , 6 healthy volunteer receive active treatment 2 healthy volunteer receive placebo standard meal . Doses 40 mg , 100 mg , 200 mg 400 mg TMC589337 TMC589354 placebo administer single oral administration . The treatment schedule make way panel 4 session healthy volunteer receive active treatment 3 time placebo . A washout period ( period treatment take view medication eliminate body start new treatment ) least 10 day respect consecutive TMC589337 , TMC589354 placebo dose within panel . Each single dosing session stagger approach meaning first 4 healthy volunteer dose 48 hour later next 4 healthy volunteer dose . Multiple dose start 200 mg session TMC589337 and/or TMC589354 find generally safe well tolerate decide Investigator Sponsor approve local ethic committee . Multiple dose TMC589337 and/or TMC589354 start plasma pk profile supportive evaluate repeat dose . The multiple dose part trial open-label include 5 panel 6 healthy adult volunteer ( Panels 3 , 4 , 5 , 6 7 ) . Each panel 1 session TMC589337 TMC589354 administer . Treatment anticipated twice daily regimen , different dose regimen test . Final dos determine accord result obtain single dose session higher total daily dose 400 mg . If multiple dosing find generally safe well tolerated Panel 3 4 , dose Panels 5-7 determine . Both Panels 3 4 , Panels 5 6 run parallel . In Panel 7 , 1 compound , either TMC589337 TMC589354 , select twice daily daily regimen 7 day . In addition , healthy volunteer Panels 3 , 4 , 5 6 receive single oral dose 300 mg TMC310911 Day 7 session assess enhance effect repeat administration TMC589337 TMC589354 pk profile single dose TMC310911 . Healthy volunteer Panel 7 receive either 300 mg dose TMC310911 dose 600 mg TMC310911 condition . Study medication give fed condition Panels 3-6 , feed fasted condition ( depend finding previous session ) Panel 7 . After washout period least 14 day healthy volunteer Panels 3 7 additional session single oral dose 300 mg ( 600 mg Panel 7 ) TMC310911 alone administer ( Sessions VIIIa , VIIIb , IXa , IXb X ) . Full pk profile TMC589337 TMC589354 determine 72 hour single dose morning dose Day 7 ( multiple dosing ) , 12 hour ( 24 hour Panel 7 give daily . ) morning dose Days 1 6 multiple dosing session . Full pk profile TMC310911 determine 24 hour give alone Day 7 TMC589337 TMC589354 multiple dosing session . Safety tolerability evaluate continuously document ( safety report ) step next dose . Dose escalation single multiple ascend dose regimen continue previous dose find safe generally well tolerated Investigator Sponsor approve ethic committee . Actual dos may adapt pending outcome previous session . The expected duration study ( exclude screen ) least 8 week . Safety tolerability evaluation record regular interval throughout trial period . Illnesses side effect monitor continuously . Blood urine sample take screening , Panel 1 2 Day 1 , 2 4 session I IV , Panel 3 7 Day 1 , 3 , 6 , 7 , 8 10 session V , VI VII , Day 1 2 session VIII , IX X 2 follow-up visit 10 14 day 30 32 day last drug intake . Electrocardiogram ( ECG ) take vital sign ( blood pressure heart rate ) measure screening , Panel 1 2 session day ( Day -1 ECGs ) , Panel 3 7 Day -1 ( ECG ) , Day 1 , 3 , 6 , 7 , 8 10 session V , VI VII Day 1 2 session VIII , IX X 2 follow-up visit . Physical examination do screening , Day 4 session Panel 1 2 , Day 6 10 session V , VI VII , Day -1 2 session VIII , IX X 2 follow-up visit . Continuous ECG data obtain first 8 hour intake study medication single dose escalation part study . TMC589337 , TMC589354 , TMC310911 placebo formulate oral drinkable solution . Panel 1-2 consist single dose TMC589337 TMC589354 placebo 40-400mg ( 2ml 5ml ) Day 1 session . Panel 3-7 consist TMC589337 , TMC589354 placebo twice daily ( daily Panel 7 ) , Day 1 Day 7 maximum daily dose 400mg ( 5ml ) plus single morning intake 300mg ( 12ml ) ( 600mg Panel 7 ) TMC310911 Day 7 Day 1 2nd session .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Nonsmokers least 3 month prior selection Weight define Body Mass Index ( BMI , weight kg divide square height meter ) 18.0 30.0 kg/m2 , extremes include Informed Consent Form ( ICF ) sign voluntarily Able comply protocol requirement Healthy basis pretrial physical examination , medical history , result blood biochemistry hematology test , urinalysis , vital sign , 12lead electrocardiogram ( ECG ) . Past history clinically significant heart arrhythmia ( extrasystolic , tachycardia rest ) baseline prolongation QTc interval &gt; 450 m , history risk factor Torsade de Pointes syndrome ( hypokalemia , family history long QT Syndrome ) Female , except postmenopausal 2 year , posthysterectomy postsurgical sterilization ( without reversal operation ) Currently active clinically relevant significant underlying gastrointestinal , cardiovascular , nervous system , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease History clinically relevant skin disease allergy include drug allergy well .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>PEPI-TiDP23-C104</keyword>
	<keyword>PEPI-C104</keyword>
	<keyword>PEPI</keyword>
	<keyword>TMC589337</keyword>
	<keyword>TMC589354</keyword>
	<keyword>TMC310911</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>